154 related articles for article (PubMed ID: 1647421)
1. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.
Huskinson-Mark J; Araujo FG; Remington JS
J Infect Dis; 1991 Jul; 164(1):170-1. PubMed ID: 1647421
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
3. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
Araujo FG; Huskinson J; Remington JS
Antimicrob Agents Chemother; 1991 Feb; 35(2):293-9. PubMed ID: 2024964
[TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of antimicrobial agents against Toxoplasma gondii.
Harris C; Salgo MP; Tanowitz HB; Wittner M
J Infect Dis; 1988 Jan; 157(1):14-22. PubMed ID: 3121760
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
7. Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.
Derouin F; Santillana-Hayat M
Antimicrob Agents Chemother; 2000 Sep; 44(9):2575-7. PubMed ID: 10952623
[TBL] [Abstract][Full Text] [Related]
8. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.
Mack DG; McLeod R
Antimicrob Agents Chemother; 1984 Jul; 26(1):26-30. PubMed ID: 6383209
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.
Araujo FG; Huskinson-Mark J; Gutteridge WE; Remington JS
Antimicrob Agents Chemother; 1992 Feb; 36(2):326-30. PubMed ID: 1605598
[TBL] [Abstract][Full Text] [Related]
10. Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine.
Derouin F; Chastang C
J Antimicrob Chemother; 1990 Apr; 25(4):708-11. PubMed ID: 2161824
[No Abstract] [Full Text] [Related]
11. New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
Ferreira RA; de Oliveira AB; Gualberto SA; Miguel Del Corral JM; Fujiwara RT; Gazzinelli Guimarães PH; de Almeida Vitor RW
Exp Parasitol; 2012 Dec; 132(4):450-7. PubMed ID: 23000485
[TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Romand S; Bryskier A; Moutot M; Derouin F
J Antimicrob Chemother; 1995 Jun; 35(6):821-32. PubMed ID: 7559193
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
Meneceur P; Bouldouyre MA; Aubert D; Villena I; Menotti J; Sauvage V; Garin JF; Derouin F
Antimicrob Agents Chemother; 2008 Apr; 52(4):1269-77. PubMed ID: 18212105
[TBL] [Abstract][Full Text] [Related]
14. Brazilian strains of Toxoplasma gondii are controlled by azithromycin and modulate cytokine production in human placental explants.
Franco PS; Gois PSG; de Araújo TE; da Silva RJ; de Freitas Barbosa B; de Oliveira Gomes A; Ietta F; Dos Santos LA; Dos Santos MC; Mineo JR; Ferro EAV
J Biomed Sci; 2019 Jan; 26(1):10. PubMed ID: 30665403
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae.
Kessl JJ; Ha KH; Merritt AK; Meshnick SR; Trumpower BL
Mol Biochem Parasitol; 2006 Apr; 146(2):255-8. PubMed ID: 16412524
[No Abstract] [Full Text] [Related]
16. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.
Ferreira RA; Oliveira AB; Ribeiro MF; Tafuri WL; Vitor RW
Exp Parasitol; 2006 Jun; 113(2):125-9. PubMed ID: 16458300
[TBL] [Abstract][Full Text] [Related]
17. Toxoplasma gondii: in vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide.
Pfefferkorn ER; Eckel ME; McAdams E
Exp Parasitol; 1988 Apr; 65(2):282-9. PubMed ID: 3350108
[TBL] [Abstract][Full Text] [Related]
18. Azithromycin treatment is able to control the infection by two genotypes of Toxoplasma gondii in human trophoblast BeWo cells.
Ribeiro M; Franco PS; Lopes-Maria JB; Angeloni MB; Barbosa BF; Gomes AO; Castro AS; Silva RJD; Oliveira FC; Milian ICB; Martins-Filho OA; Ietta F; Mineo JR; Ferro EAV
Exp Parasitol; 2017 Oct; 181():111-118. PubMed ID: 28803905
[TBL] [Abstract][Full Text] [Related]
19. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.
Hudson AT; Dickins M; Ginger CD; Gutteridge WE; Holdich T; Hutchinson DB; Pudney M; Randall AW; Latter VS
Drugs Exp Clin Res; 1991; 17(9):427-35. PubMed ID: 1822435
[TBL] [Abstract][Full Text] [Related]
20. Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro.
Jin C; Kaewintajuk K; Jiang J; Jeong W; Kamata M; Kim HS; Wataya Y; Park H
Exp Parasitol; 2009 Feb; 121(2):132-6. PubMed ID: 18977350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
